Sarepta Therapeutics
Spareta Therapeutics seeks an experienced scientist to join the RNA Research group's discovery chemistry team in Bedford, MA. This role focuses on designing, synthesizing, and characterizing novel oligonucleotide conjugates and delivery methods for next-generation RNA therapeutics targeting Duchenne muscular dystrophy and other diseases.
Headquarters
Cambridge, Massachusetts, United States
Company Size
1001-5000 employees
We are focused on the development of precision genetic medicines to treat rare neuromuscular and central nervous system diseases. Learn more about Sarepta.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Sarepta Therapeutics.
Right around the average for this role
Sarepta Therapeutics CEO Doug Ingram will retire after a tumultuous decade
2 weeks ago
Oligonucleotide Chemistry, Co-Op
Dyne Therapeutics
Synthesis Scientist
Eli Lilly and Company
Scientist III, Discovery Chemistry (Synthetic Chemistry)
Arrowhead Pharmaceuticals
Sr. Scientist/Staff Scientist: Nucleotide and Nucleic Acid Chemistry
Atlas Data Storage
Scientist, RNA Chemistry
Dyne Therapeutics
Process Discovery Chemist
GSK plc